Repare Therapeutics (NASDAQ:RPTX) Receives "Buy" Rating from HC Wainwright

Repare Therapeutics (NASDAQ:RPTX - Get Free Report)'s stock had its "buy" rating reiterated by HC Wainwright in a research note issued to investors on Thursday, Benzinga reports. They presently have a $10.00 target price on the stock. HC Wainwright's price objective suggests a potential upside of 196.74% from the company's current price.

Separately, Lifesci Capital raised shares of Repare Therapeutics to a "strong-buy" rating in a report on Monday, July 29th.

Repare Therapeutics Trading Down 1.7 %

RPTX traded down $0.06 during trading on Thursday, reaching $3.37. 39,908 shares of the company's stock were exchanged, compared to its average volume of 166,738. Repare Therapeutics has a one year low of $2.71 and a one year high of $8.49. The stock has a market capitalization of $143.06 million, a PE ratio of -2.01 and a beta of 0.72. The firm has a fifty day moving average price of $3.22 and a two-hundred day moving average price of $3.39.

Repare Therapeutics (NASDAQ:RPTX - Get Free Report) last posted its earnings results on Tuesday, August 6th. The company reported ($0.82) earnings per share for the quarter, topping analysts' consensus estimates of ($0.85) by $0.03. Repare Therapeutics had a negative net margin of 99.76% and a negative return on equity of 31.11%. The firm had revenue of $1.07 million for the quarter, compared to analyst estimates of $4.02 million. Sell-side analysts expect that Repare Therapeutics will post -2.15 earnings per share for the current year.

Institutional Investors Weigh In On Repare Therapeutics

Institutional investors have recently modified their holdings of the company. Acadian Asset Management LLC boosted its stake in shares of Repare Therapeutics by 212.1% in the 2nd quarter. Acadian Asset Management LLC now owns 417,929 shares of the company's stock valued at $1,373,000 after purchasing an additional 284,036 shares during the last quarter. Blue Owl Capital Holdings LP boosted its stake in shares of Repare Therapeutics by 8.0% in the 2nd quarter. Blue Owl Capital Holdings LP now owns 3,372,499 shares of the company's stock valued at $11,129,000 after purchasing an additional 250,000 shares during the last quarter. XTX Topco Ltd bought a new stake in shares of Repare Therapeutics in the 2nd quarter valued at $110,000. Marshall Wace LLP bought a new stake in shares of Repare Therapeutics in the 2nd quarter valued at $273,000. Finally, Vontobel Holding Ltd. boosted its stake in shares of Repare Therapeutics by 20.0% in the 3rd quarter. Vontobel Holding Ltd. now owns 24,000 shares of the company's stock valued at $83,000 after purchasing an additional 4,000 shares during the last quarter. 85.09% of the stock is owned by institutional investors.

Repare Therapeutics Company Profile

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.